July 3rd 2009 - Palumed received a support of Oséo-France for its antibiotic program- Oséo decided to support a consortium "Nosobio", composed of 4 biotech companies (Palumed, DaVolterra, Serial Genetics, Genewave) and two academic teams from Beaujon Hospital-Paris and the Pasteur Institut, focused on the fight of nosocomial infections. Three different approaches are developed by the consortium: prevention, diagnostic and therapy. The support of Oséo will help Palumed to develop its anti-MRSA drug-candidate, the vancomyquine® PA1409 over a 3-year period (2009-2011)... Palumed's Press Release - communiqué de presse de Palumed - Genewave's Press Release - PDF du communiqué de presse Genewave -...
About Palumed
PALUMED S. A. is a young company founded in December 2000 to create and develop new antimalarial agents and new antibacterial molecules.
PALUMED has been named after "paludisme", the french word for malaria. PALUMED is co-owner of 6 patent applications filed between 2003 and 2007: two on antimalarials (trioxaquines®), one on new anti-schistosomiase agents, two on new antibiotics (antibioquines®) and one on new copper chelating agents... About Palumed -
